The invention discloses application of entacapone to prevention or treatment of obesity and other metabolic syndromes. Specifically, the invention discloses application of entacapone as shown in the formula I or a pharmaceutically acceptable salt thereof to preparation of medicaments for the prevention and / or treatment of metabolic diseases, cardiovascular and cerebrovascular diseases, as well as liver, kidney and thyroid diseases induced therefrom. The metabolic disease is selected from obesity, diabetes and hyperlipidemia; the cardiovascular and cerebrovascular disease is selected from hypertension, coronary heart disease, and atherosclerosis. The prevention and / or treatment of obesity refers to inhibition of body weight increase or promotion of weight loss. The blood lipid is selected from the group consisting of low density lipoprotein, low density lipoprotein-cholesterol, cholesterol and triglyceride. The renal disease is selected from diabetic nephropathy. (img file = 'DDA00002485677700011.TIF' wi = '1113' he = '654' /).